HomeQuestionsGI Oncologist for opinions on GLP1RA vs Aspirin for Colorectal Cancer Prev I'm working on a fast turnaround news story for MedCentral with a Monday AM deadline. For this, I'm looking for an oncologist or colorectal cancer specialist to provide detailed insights on an abstract to be presented at ASCO GI this weekend: GLP-1 receptor agonist vs aspirin for primary prevention of colorectal cancer: Evidence from a real-world head-to-head comparison. https://www.asco.org/abstracts-presentations/255085 Here are my questions: Study significance 1. Why is this first real-world, head-to-head comparison of GLP-1 receptor agonists versus aspirin for colorectal cancer prevention clinically and scientifically important? Clinical implications 2. How should clinicians interpret these findings when considering colorectal cancer prevention in patients already eligible for GLP-1 therapy for obesity or diabetes? Future research 3. What prospective studies are needed to confirm these results and define which patients are most likely to benefit from GLP-1 receptor agonists for cancer prevention?

GI Oncologist for opinions on GLP1RA vs Aspirin for Colorectal Cancer Prev I'm working on a fast turnaround news story for MedCentral with a Monday AM deadline. For this, I'm looking for an oncologist or colorectal cancer specialist to provide detailed insights on an abstract to be presented at ASCO GI this weekend: GLP-1 receptor agonist vs aspirin for primary prevention of colorectal cancer: Evidence from a real-world head-to-head comparison. https://www.asco.org/abstracts-presentations/255085 Here are my questions: Study significance 1. Why is this first real-world, head-to-head comparison of GLP-1 receptor agonists versus aspirin for colorectal cancer prevention clinically and scientifically important? Clinical implications 2. How should clinicians interpret these findings when considering colorectal cancer prevention in patients already eligible for GLP-1 therapy for obesity or diabetes? Future research 3. What prospective studies are needed to confirm these results and define which patients are most likely to benefit from GLP-1 receptor agonists for cancer prevention?

Asked by MedCentral

Asked 3 months ago

Reviewed by Featured.com

Healthcare & Biotech

1 Answers

Cameron Rokhsar

Founder & Medical Director at New York Cosmetic Skin & Laser Surgery Center

Answered 3 months ago

I'm a dermatologist, but I follow this because patients use GLP 1 drugs. In the ASCO GI abstract, a matched TriNetX head to head study of 281,656 patients found colorectal cancer in 0.13% of GLP 1 users vs 0.176% of aspirin users, risk ratio 0.741. That comparison helps because aspirin's bleeding risk changes who can stay on it. If you already plan GLP 1 therapy for diabetes or obesity, think of this as a possible extra benefit. Do not replace screening. A 2025 matched cohort review found overall cancer incidence 13.6 vs 16.4 per 1,000 person years with GLP 1 use, HR 0.83. We now need prospective trials with adenoma and CRC endpoints, clear dose duration, and prespecified subgroups like age under 45, tobacco use, and family history.

1 Answers

Cameron Rokhsar

Related Questions

1 Answers

Cameron Rokhsar